| 生物活性 |
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
|
|---|---|
| 分子量 |
145.83 kDa
|
| CAS号 |
1638338-43-8
|
| 中文名称 |
那赛昔珠单抗
|
| 运输条件 |
Shipping with dry ice.
|
| 储存方式 |
Store at -20˚C
|
纯度： 99%
咨询热线：
400-881-9290
Data Sheet
